Member Info for Timster

Watch the tucandoom breakdown live on LSE🍿

Good to see the real experts are on board....

Dox delivered in therapeutic levels directly to tumours with no recorded cardiotoxicity or dox damaging whatever it comes in to contact with in the body on its way to tumours.

No contest, straight dox will always be the winner.......

Don't know what Avacta were thinking to be honest.

It's all a scam, the conclusion on the poster says it works, but it doesn't.

Those seeing good results on the trial with large reduction in tumours are just actors.

Avacta have played a blinder fooling the FDA, the scientific advisory board and all those cancer hubs running the trials.

All targets met for H2 now LDA, that's the RNS we've all been waiting for, reset the H2 calender calculator.

"Imagine the twatter narrative."

Just like the massive reaction to ESMO.

It's been monumental today as expected.

Still works.

2 weekly cohorts must be finishing soon surely.

It works:

AVA6000 delivers high concentration of free dox to the TME relative to plasma, resulting in antitumor activity in FAPhigh tumor types with reduced systemic dox exposure, resulting in lower toxicity versus conventional dox.

Just waiting for the regulatory process now, patience is required.

Nfts you seem to be hinting at some inside knowledge?

The issue with being on AIM is that unless the pipeline includes immediate funding from partners it will be ignored.

To long term investors though it will be very interesting to see what's lined up.

Click bait garbage...

Best ignore the green box tucandoom.

Great thread, hopefully the pipeline will already have some financially backing lined up.

he's clearly worked as a trader, but talks utter ******

Size buys, usual suspects, watch the bid, CAR-T etc etc

Massive week next week, holiday season over, RNS's queued up....

ESMO will have as much of an effect on the SP as AACR had.

More opportunity for Avacta to get the word out, I'd imagine the same attendees would be at ESMO as that were at AACR.

Posters at ESMO, AACR, ASCO are not the news we are waiting for.

Indications selected for P2 will be very interesting but not SP influencing id imagine as it's another long wait till efficacy will be officially reported.

Licence deals is probably the only thing that matters to the market.

Buy out or non dilutive funding options.

No doubt it will be £200 ex chin-ah after ESMO though.

Fantastic news for Avacta. What with the CAR-T pipeline...

It's just a poster, might be an updated one but to be fair AACR poster was pretty impressive.

Well it seems the market doesn't care Tony sold his shares.

Give it a rest watching x